Positive News SentimentPositive NewsNASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $0.44 +0.01 (+3.05%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Telomir Pharmaceuticals Stock (NASDAQ:TELO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TELO alerts:Sign Up Key Stats Today's Range$0.44▼$0.4450-Day Range$0.42▼$1.2552-Week Range$0.40▼$1.58Volume23,092 shsAverage Volume123,171 shsMarket Capitalization$32.12 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Telomir Pharmaceuticals is a biotechnology company focused on developing treatments based on research into telomeres, the protective structures at the ends of chromosomes, and cellular metal regulation. Its lead investigational candidate, Telomir-1, is a small molecule being studied for its potential to affect telomere biology. The company has described possible applications in cancer and age-related conditions; these uses remain under investigation. Telomir-1 is an experimental product, not an approved medicine. The company’s work is at an early development stage, and its research has not established the candidate’s safety or effectiveness as a treatment.AI Generated. May Contain Errors. Read More Telomir Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreTELO MarketRank™: 1.997866097625 of 5 starsTelomir Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 662nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingTelomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTelomir Pharmaceuticals has a consensus price target of $4.00, representing about 845.4% upside from its current price of $0.42.Amount of Analyst CoverageTelomir Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Telomir Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTelomir Pharmaceuticals has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Telomir Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.22% of the float of Telomir Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTelomir Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Telomir Pharmaceuticals has recently decreased by 2.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelomir Pharmaceuticals does not currently pay a dividend.Dividend GrowthTelomir Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentTelomir Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.36% of the stock of Telomir Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTelomir Pharmaceuticals has minimal institutional ownership at this time.Read more about Telomir Pharmaceuticals' insider trading history. Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TELO Stock News HeadlinesTelomir Selects Linical to Support Phase 1/2 Cancer Trial37 minutes ago | tipranks.comTelomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer1 hour ago | globenewswire.comThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.November 18 at 1:00 AM | Patriot Gold Group (Ad)Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 7, 2026 | marketscreener.comMTelomir Pharmaceuticals, Inc. announced that it has received $5.618228 million in fundingOctober 6, 2026 | marketscreener.comMTelomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyOctober 6, 2026 | globenewswire.comResearch shows Telomir-Zn might slow bone cancer in dogsSeptember 24, 2026 | msn.comMaxim Initiates Telomir Pharmaceuticals at Buy With $4 Price TargetSeptember 18, 2026 | marketscreener.comMSee More Headlines TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $1.33 at the start of the year. Since then, TELO stock has decreased by 68.2% and is now trading at $0.4231. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) posted its quarterly earnings results on Friday, November, 6th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an IPO on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO. Who are Telomir Pharmaceuticals' major shareholders? Top institutional shareholders of Telomir Pharmaceuticals include State Street Corp (0.08%). How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/06/2026Today11/18/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 6 days, TELO's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CIK1971532 Webtelomirpharma.com Phone(786) 396-6723FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Telomir Pharmaceuticals$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+845.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-107.89% Return on Assets-94.72% Debt Debt-to-Equity RatioN/A Current Ratio19.58 Quick Ratio19.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book7.05Miscellaneous Outstanding Shares73,680,000Free Float61,623,000Market Cap$31.17 million OptionableN/A Beta-0.19 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:TELO) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.